Everything You Need to Know About Valiant Laboratories’ September 27 Initial Public Offering

Valiant Laboratories, a company that produces pharmaceutical ingredients, has made the decision to begin its inaugural share sale for public subscription on September 27.

According to the red herring prospectus submitted to Sebi on Friday, the initial public offering (IPO), which is a completely new issue of 1.08 crore equity shares without an offer-for-sale component, would be completed on October 3. On October 5, shares will be distributed, and on October 9, the business will list its shares on the stock exchange. Additionally, on September 26 bids for anchor investors will be accepted.

Through its subsidiary, Valiant Advanced Sciences Private Ltd., the proceeds of the offering will be used to establish a production facility for specialty chemicals in Gujarat and to fulfill the working capital needs of the subsidiary firm.

Total shares issued in the IPO are 5,45,77,464 in number. A total of 50% has been set aside for eligible institutional purchasers, 15% for non-institutional investors, and 35% for individual investors. Investors may make offers for a minimum of 105 shares or multiples of that number.

Today’s Yatra Online IPO GMP

Market watchers claim that Valiant Laboratories’ current grey market premium is nil. This indicates that the grey market anticipates no listing benefit from the public concern. Importantly, the GMP of unlisted shares fluctuates dependent on market sentiment.

Investors’ willingness to pay more than the issue price is indicated by the term “grey market premium.”

Concerning Valiant Laboratories

With a concentration on producing paracetamol, which is used to treat headache, muscular discomfort, arthritis, backache, toothache, cold, and fever, Valiant Laboratories is a manufacturer of active pharmaceutical ingredients or bulk drugs.

The demand from domestic formulation manufacturers and export helped the paracetamol API industry grow from Rs 2,200 crore in fiscal 2017 to Rs 3,900 crore in fiscal 2023. Going forward, the industry is predicted to grow at a CAGR (Compound Annual Growth Rate) of 5-7% between fiscal 2023 and fiscal 2027.

The only book-running lead manager for the issue is Unistone Capital Pvt. The company’s equity shares will be listed on the BSE and NSE.